The ARHGAP36 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma cell line to disrupt the ARHGAP36 gene. This loss-of-function model enables systematic investigation of ARHGAP36??s role in cancer cell biology without the need for clonal isolation, preserving the natural genetic variability of a heterogeneous pool. The polyclonal format is particularly suitable for studying population-level responses to gene disruption and allows direct comparison with parental A-549 cells in functional assays.
The parental A-549 cell line originates from the lung carcinoma of a 58-year-old Caucasian male and serves as a well-established model for type II alveolar epithelial cells. These adherent cells feature a KRAS G12S activating mutation and wild-type p53, providing a genetically defined background that mimics key oncogenic drivers of non-small cell lung cancer. Their epithelial nature and retained characteristics of alveolar basal cells make them an appropriate platform for dissecting signaling pathways that govern cytoskeletal dynamics, adhesion, and migration.
ARHGAP36 functions primarily as a guanine nucleotide exchange factor (GEF) for RAC1 and CDC42, catalyzing their conversion to active GTP-bound states. This activity is stimulated by upstream EGF/EGFR and TGF-?? signaling, leading to activation of PAK, LIMK, and Cofilin, which coordinate actin dynamics. ARHGAP36-mediated RAC1/CDC42 activation also engages PI3K/Akt, promoting proliferation and survival. The protein directly interacts with 14-3-3 proteins and actin, controlling cytoskeletal remodeling at focal adhesions. Through these interactions, ARHGAP36 integrates signaling inputs to regulate cell motility and growth.
In the context of A-549 lung adenocarcinoma cells, ARHGAP36 is poised to amplify oncogenic signals driven by KRAS G12S, as both pathways converge on RAC1/CDC42-mediated actin reorganization and PI3K/Akt-dependent proliferation. Disruption of ARHGAP36 in these polyclonal knockout cells is therefore anticipated to attenuate migratory and invasive capacities, providing a direct means to evaluate its contribution to metastatic phenotypes. This model is particularly valuable for exploring the functional interplay between ARHGAP36 and mutant KRAS in driving non-small cell lung cancer progression, and for identifying signaling nodes that could be therapeutically targeted to hinder metastasis.
Researchers can employ these polyclonal knockout cells in Rac1/Cdc42 activation assays, Western blotting for downstream targets such as phospho-PAK and phospho-Cofilin, Transwell migration and invasion assays, and phalloidin staining to visualize actin reorganization. The cells are also suitable for RNA-seq to profile transcriptional changes upon ARHGAP36 loss and for co-immunoprecipitation studies to map altered protein interactions. These applications make the product an essential tool for dissecting Rho GTPase-dependent cancer cell behavior and validating genetic interactions in lung adenocarcinoma. For further details, including protocols and validation data, please contact Ascent Research.
